Introduction
============

Cancer is a leading cause of death worldwide, with millions of individuals succumbing to various types of cancer annually ([@b1-etm-04-04-0762]). Therefore, it is of utmost importance to identify anticancer prevention and treatment strategies. According to epidemiology, cell apoptosis plays a role in the incidence of cancers. Apoptosis, also known as programmed cell death, is a fundamentally important biological process triggered by a variety of stimuli, including deprivation of growth/survival factors, exposure to cytotoxic drugs or DNA damaging agents, activation of death receptors and activity of cytotoxic cells, that is involved in controlling cell number and eliminating harmful or virus-infected cells to maintain cell homeostasis ([@b2-etm-04-04-0762]--[@b4-etm-04-04-0762]). The inappropriate process of apoptosis potentially results in various pathological disorders ([@b5-etm-04-04-0762]). The caspase family (cysteine and aspartic proteases) is mainly involved in the regulation of cell apoptosis ([@b6-etm-04-04-0762]), and has two major functions: caspase-1, −4, −5 and −11, as initiator caspases, are primarily involved in the processing and activation of pro-inflammatory cytokines, while caspase-2, −3, −6, −7, −8 and −9, as executor caspases, play a role in the execution phase of apoptosis ([@b6-etm-04-04-0762],[@b7-etm-04-04-0762]). CASP activation has two dinstinct albeit converging pathways: the extrinsic or receptor-mediated pathway, and the intrinsic or mitochondrial pathway. These two pathways possess an independent group of initiator caspases despite using the same group of effector caspases ([@b8-etm-04-04-0762]--[@b10-etm-04-04-0762]). Caspase-8 (CASP-8) is essential for the extrinsic cell death pathways initiated by the TNF family members with the formation of the death-inducing signaling complex ([@b11-etm-04-04-0762]).

Single-nucleotide polymorphisms (SNPs) are the most common form of human genetic variation, leading to susceptibility to cancer. Findings of previous studies showed that some variants in CASP-8 gene are associated with susceptibility to various human cancers ([@b12-etm-04-04-0762],[@b13-etm-04-04-0762]). A case-control study in a Chinese population found that CASP-8 −652 6N del/del genotypes showed a multiplicative joint effect with FasL and Fas in attenuating susceptibility to pancreatic cancer ([@b14-etm-04-04-0762]). However, relevant studies on −652 6N del in CASP-8 are inconclusive and inconsistent. Therefore, a human genome epidemiology (HuGE) review and meta-analysis were conducted, including the most recent and relevant articles in order to identify statistical evidence of the association between the CASP-8 −652 6N ins/del polymorphism and cancer risk that have been investigated.

Materials and methods
=====================

Literature search
-----------------

An extensive electronic search of the PubMed, Cochrane Library, Embase, Web of Science, SpringerLink, CNKI and CBM databases was performed to identify relevant studies available up to May 1, 2012. The search terms used included \['caspase-8', 'CASP-8' or 'Caspase 8' (Mesh)\] and \['SNPs', 'SNP' or 'polymorphism, genetic' (Mesh)\] and \['cancer', 'tumor' or 'Neoplasms' (Mesh)\]. The references in the eligible studies or textbooks were also reviewed to check through manual searches to find other potentially eligible studies.

Inclusion and exclusion criteria
--------------------------------

The included studies had to meet the following criteria: i) case-control study focused on the associations between CASP-8 −652 6N ins/del polymorphism and cancer risk; ii) all patients diagnosed with a malignant tumor confirmed by pathological examination of the surgical specimen; iii) the frequencies of alleles or geno-types in case and control groups could be extracted; iv) the publication was in English or Chinese. Studies were excluded when they were: i) not case-control studies about CASP-8 −652 6N ins/del polymorphism and cancer risk; ii) based on incomplete data; iii) useless or overlapping data were reported; iv) meta-analyses, letters, reviews or editorial articles.

Data extraction
---------------

Using a standardized form, data from published studies were extracted independently by two reviewers to populate the necessary information. The information extracted from each of the articles included: first author, year of publication, country, language, ethnicity, study design, source of cases and controls, number of cases and controls, mean age, sample, cancer type, genotype method, allele and genotype frequency, and evidence of Hardy-Weinberg equilibrium (HWE) in controls. In case of conflicting evaluations, an agreement was reached following a discussion with a third reviewer.

Quality assessment of included studies
--------------------------------------

Two reviewers independently assessed the quality of papers according to modified STROBE quality score systems ([@b15-etm-04-04-0762],[@b16-etm-04-04-0762]). Forty assessment items associated with the quality appraisal were used in this meta-analysis, scores ranging from 0 to 40. Scores of 0--20, 20--30 and 30--40 were defined as low, moderate and high quality, respectively. Disagreement was resolved by discussion.

Statistical analysis
--------------------

The odds ratio (OR) and 95% confidence interval (95% CI) were calculated using Review Manager Version 5.1.6 (provided by the Cochrane Collaboration, available at: <http://ims.cochrane.org/revman/download>) and STATA Version 12.0 (Stata Corp., College Station, TX, USA) software. Between-study variations and heterogeneities were estimated using Cochran's Q-statistic ([@b17-etm-04-04-0762],[@b18-etm-04-04-0762]) (P≤0.05 was considered to be a manifestation of statistically significant heterogeneity). The effect of heterogeneity, ranging from 0 to 100% and representing the proportion of inter-study variability that can be contributed to heterogeneity rather than to chance, was quantified using the I2 test. When a significant Q-test (P≤0.05) or I^2^\>50% indicated that heterogeneity among studies existed, the random-effects model was employed for the meta-analysis. Otherwise, the fixed-effects model was used. To establish the effect of heterogeneity on conclusions of the meta-analyses, a subgroup analysis was carried out. We also tested whether genotype frequencies of controls were in HWE using the χ^2^ test. Funnel plots are often used to detect publication bias. However, due to its limitations caused by varied sample sizes and subjective reviews, Egger's linear regression test, which measures the funnel plot's asymmetry using a natural logarithmic scale of OR, was used to evaluate the publication bias ([@b19-etm-04-04-0762]). When the P-value is \<0.1, publication bias is considered significant. All the P-values were two-sided. To ensure the reliability and accuracy of the results, two reviewers populated the data in the statistical software programs independently and obtained identical results.

Results
=======

Characteristics of included studies
-----------------------------------

Subsequent to the initial screening a total of 105 relevant publications were identified. Nineteen studies ([@b20-etm-04-04-0762]--[@b37-etm-04-04-0762]) appeared to have met the inclusion criteria and were subjected to further examination. The flow chart of study selection is shown in [Fig. 1](#f1-etm-04-04-0762){ref-type="fig"}. In the pooled analysis, a total of 23,172 cancer cases and 26,532 healthy controls from 19 studies were included and addressed. The publication year of involved studies ranged from 2006 to 2011. Twelve of these studies were conducted in Asian populations, 6 in Caucasian populations and 1 in African populations. The HWE test was performed on the genotype distribution of the controls in all the included studies, 2 of these studies were out of HWE ([@b34-etm-04-04-0762],[@b37-etm-04-04-0762]) and the remaining studies showed to be in HWE (P\>0.05). Quality scores of included studies were \>20 (moderate-high quality). The characteristics and methodological quality of the included studies are shown in [Table I](#t1-etm-04-04-0762){ref-type="table"}. The genotype distribution of the CASP-8 −652 6N ins/del polymorphism in the case and control groups is shown in [Table II](#t2-etm-04-04-0762){ref-type="table"}.

Main results and subgroup analysis
----------------------------------

A summary of the meta-analysis findings of the association between CASP-8 −652 6N ins/del polymorphism and cancer risk is provided in [Table III](#t3-etm-04-04-0762){ref-type="table"}. The meta-analysis results showed that the del allele, del allele carrier and ins/del genotypes of −652 6N ins/del in CASP-8 gene were negatively associated with cancer risk (OR=0.91, 95% CI=0.84--0.98, P=0.01; OR=0.88, 95% CI=0.80--0.96, P=0.005; OR=0.91, 95% CI=0.85--0.98, P\<0.001; respectively) ([Figs. 2](#f2-etm-04-04-0762){ref-type="fig"}--[4](#f4-etm-04-04-0762){ref-type="fig"}), while no significant correlation was observed between the del/del genotypes of −652 6N ins/del and cancer risk (OR=0.89, 95% CI=0.79--1.01, P=0.08). In the subgroup analysis by ethnicity, we found that the del allele of −652 6N ins/del was a protective factor for cancer risk in the Caucasian and Asian populations (OR=0.96, 95% CI=0.93--1.00, P=0.05; OR=0.86, 95% CI=0.75--1.00, P=0.05; respectively), although not in the African population (OR=1.01, 95% CI=0.87--1.18, P=0.891). For the del allele carrier of −652 6N ins/del polymorphism, negative associations with cancer risk were found in the Caucasian population (OR=0.89, 95% CI=0.83--0.97, P=0.005), but not in the Asian and African populations (OR=0.86, 95% CI=0.73--1.01, P=0.06; OR=1.13, 95% CI=0.88--1.47, P=0.33; respectively). Notably, no associations were found between the del/del genotype (variant homozygote) of the −652 6N ins/del polymorphism and cancer risk in the three populations (OR=0.89, 95% CI=0.79--1.10, P=0.08). However, with regards to the ins/del genotype (heterozygote) of the −652 6N ins/del polymorphism, protective associations with cancer risk were found in the Caucasian population (OR=0.91, 95% CI=0.84--0.98, P=0.01), whereas no correlation was found in the Asian and African populations (OR=0.91, 95% CI=0.80--1.03, P=0.14; OR=1.18, 95% CI=0.95--1.47, P=0.14; respectively).

Publication bias
----------------

Publication bias of the literature was accessed by Begger's funnel plot and Egger's linear regression test. Egger's linear regression test was used to measure the asymmetry of the funnel plot. The graphical funnel plots of included studies appeared to be symmetrical ([Fig. 5](#f5-etm-04-04-0762){ref-type="fig"}). Egger's test also showed that there was no statistical significance for all evaluations of publication bias (all P\>0.05). Findings of Egger's publication bias test are shown in [Table IV](#t4-etm-04-04-0762){ref-type="table"}.

Discussion
==========

CASP-8, located on chromosome 2q33--q34, encoded by the CASP-8 gene, is a caspase protein that plays a key role in the execution-phase of cell apoptosis ([@b28-etm-04-04-0762]). When induced by Fas and various apoptotic stimuli, this protein is involved in apoptosis ([@b29-etm-04-04-0762]). Caspase-8 is known to activate during death receptor-initiated apoptosis, inducing apoptosis and maintaining immune homeostasis and immune surveillance, while the single genetic variants in CASP-8 and their function in human cancer susceptibility remain to be elucidated ([@b21-etm-04-04-0762]). The −652 6N ins/del (rs3834129), a common SNP in the CASP-8 gene, is strongly associated with the CASP-8 expression. Investigators have reported a correlation between the −652 6N ins/del polymorphism and susceptibility to various types of cancer. Sun *et al* observed that the CASP-8 −652 6N ins/del allele was associated with a reduced risk of developing different types of human cancer, including lung, esophageal, colorectal, cervical and breast cancer, as well as gastric cancer, indicating that this variant allele may confer protection against multiple cancers ([@b21-etm-04-04-0762]). Frank *et al* showed that the CASP-8 −652 6N ins/del variant has no significant effect on breast cancer risk in Europeans ([@b23-etm-04-04-0762]). In their study, Li *et al* observed that the CASP-8 −652 6N ins/del variant genotypes (ins/del, ins/del+del/del) were associated with significantly lower cutaneous melanoma risk than were the ins/ins genotypes ([@b24-etm-04-04-0762]). In our study, we examined the association of the −652 6N ins/del polymorphism in the CASP-8 gene with the risk for cancer by meta-analysis. A negative association was observed between the del allele, del allele carrier and ins/del genotype of the −652 6N ins/del polymorphism in CASP-8 gene and cancer risk. In the stratified analysis by ethnicity, Caucasians who harbored the ins/del genotypes or del allele or del allele carrier were found to exhibit a significantly lower risk for cancer. In addition, a negative association was also found between the del allele of −652 6N ins/del in CASP-8 gene and cancer risk in the Asian population.

Limitations of this study should be acknowledged. First, although the funnel plot and Egger's test did not show any publication bias, selection bias may have occurred because only studies published in English or Chinese were included. Second, the control subjects of the present study might not be representative of the general population, necessitating well-designed population-based studies with large sample sizes and detailed exposure information to validate our findings. Third, there was significant between-study heterogeneity from studies of the −652 6N ins/del polymorphism, while the geno-type distribution also showed deviation from HWE in some studies. Fourth, our meta-analysis was based on unadjusted OR estimates as not all published studies presented adjusted ORs, or when they did, the ORs were not adjusted by the same potential confounders, such as age, gender, ethnicity and exposures. In addition, our analysis did not consider the possibility of gene-gene or SNP-SNP interactions or the possibility of linkage disequilibrium between polymorphisms. Therefore, our conclusions should be interpreted with caution.

In conclusion, findings of this study have shown a common insertion-deletion variation in the promoter region of the CASP-8 gene as a low penetrance susceptibility locus for certain common types of human cancers. The del allele, del allele carrier and ins/del genotype of the −652 6N ins/del polymorphism in CASP-8 gene may serve as protective factors for cancer risk. However, these findings should be validated by large-scale, prospective studies investigating more diverse ethnic groups and more detailed environmental exposure data.

We would like to thank J.L. Liu (MedChina medical information service Co., Ltd.) for his valuable contribution and kindly revising the manuscript.

![Flow chart shows study selection procedure. Nineteen case-control studies were included in this meta-analysis.](ETM-04-04-0762-g00){#f1-etm-04-04-0762}

![Associations between del allele of the −652 6N ins/del polymorphism and cancer risk.](ETM-04-04-0762-g01){#f2-etm-04-04-0762}

![Associations between the del allele carrier of the −652 6N ins/del polymorphism and cancer risk.](ETM-04-04-0762-g02){#f3-etm-04-04-0762}

![Associations between the ins/del genotype of the −652 6N ins/del polymorphism and cancer risk.](ETM-04-04-0762-g03){#f4-etm-04-04-0762}

![Begger's funnel plot of publication bias.](ETM-04-04-0762-g04){#f5-etm-04-04-0762}

###### 

Characteristics of individual studies in this meta-analysis.

  Authors (Refs.)                                  Year   Country        Case no.   Sample   Genotype method   Cancer type   Quality scores         
  ------------------------------------------------ ------ -------------- ---------- -------- ----------------- ------------- ---------------------- ----
  Son *et al* ([@b20-etm-04-04-0762])              2006   Korea          432        432      Blood             PCR-RFLP      Lung cancer            27
  Sun *et al* ([@b21-etm-04-04-0762])              2007   China          4995       4972     Blood             PCR-RFLP      Mixed cancer           23
  Cybulski *et al* ([@b22-etm-04-04-0762])         2008   Poland         618        531      Blood             AS-PCR        Mixed cancer           20
  Frank *et al* ([@b23-etm-04-04-0762])            2008   Germany        7753       7921     Blood             FFA           Breast cancer          23
  Li *et al* ([@b24-etm-04-04-0762])               2008   China          805        835      Blood             PCR-RFLP      Melanoma               26
  Pittman *et al* ([@b25-etm-04-04-0762])          2008   UK             4016       3749     Blood             AS-PCR        Colorectal cancer      21
  Yang *et al* ([@b14-etm-04-04-0762])             2008   China          397        907      Blood             PCR-RFLP      Pancreatic cancer      24
  Gangwar *et al* ([@b26-etm-04-04-0762])          2009   India          212        250      Blood             PCR-RFLP      Bladder cancer         29
  Wang *et al* ([@b27-etm-04-04-0762])             2009   China          365        368      Blood             PCR-RFLP      Bladder cancer         26
  Li *et al* ([@b28-etm-04-04-0762])               2010   USA            1023       1052     Blood             PCR-RFLP      Head and neck cancer   26
  Liu *et al* ([@b29-etm-04-04-0762])              2010   China          373        838      Blood             PCR-RFLP      Colorectal cancer      25
  Lv *et al* ([@b30-etm-04-04-0762])               2010   China          100        544      Blood             TaqMan        Lymphoma               26
  Srivastava *et al* ([@b31-etm-04-04-0762])       2010   India          230        230      Blood             PCR-RFLP      Gallbladder cancer     24
  Chatterjee *et al* ([@b32-etm-04-04-0762])       2011   South Africa   445        1221     Blood             PCR-RFLP      Cervical cancer        18
  Hart *et al* ([@b33-etm-04-04-0762])             2011   Norway         442        440      Blood/tissue      TaqMan        Lung cancer            20
  Kesarwani *et al* ([@b34-etm-04-04-0762])        2011   India          175        198      Blood             PCR-RFLP      Prostate cancer        24
  Ma *et al* ([@b35-etm-04-04-0762])               2011   China          218        285      Blood             Mass-Array    Ovarian cancer         18
  Theodoropoulos *et al* ([@b36-etm-04-04-0762])   2011   Greece         402        480      Blood             PCR-RFLP      Colorectal cancer      18
  Umar *et al* ([@b37-etm-04-04-0762])             2011   India          259        259      Blood             PCR-RFLP      Esophageal cancer      20

PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism; AS, allele specific; FFA, Fluorescent fragment analysis.

###### 

The genotype distribution of CASP-8 −652 6N polymorphism in case and control groups.

  Authors (Refs.)                                  Case   Control   HWE test                                                                                
  ------------------------------------------------ ------ --------- ---------- ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ---------
  Son *et al* ([@b20-etm-04-04-0762])              432    654       210        247    160    25     432    659    205    249    161    22     0.38   0.54   HWE
  Sun *et al* ([@b21-etm-04-04-0762])              4938   7917      1959       3173   1571   194    4919   7373   2465   2771   1831   317    0.39   0.53   HWE
  Cybulski *et al* ([@b22-etm-04-04-0762])         1103   1184      1022       317    550    236    965    1047   883    274    499    192    1.68   0.20   HWE
  Frank *et al* ([@b23-etm-04-04-0762])            7390   7592      7188       1946   3700   1744   7693   7767   7619   1949   3869   1875   0.27   0.60   HWE
  Li *et al* ([@b24-etm-04-04-0762])               805    871       739        243    385    177    835    854    816    207    440    188    2.47   0.12   HWE
  Pittman *et al* ([@b25-etm-04-04-0762])          3879   3887      3871       995    1897   987    3661   3656   3666   892    1872   897    1.88   0.17   HWE
  Yang *et al* ([@b14-etm-04-04-0762])             397    647       147        268    111    18     907    1365   449    521    323    63     1.76   0.19   HWE
  Gangwar *et al* ([@b26-etm-04-04-0762])          212    326       98         121    84     7      250    367    133    133    101    16     0.30   0.58   HWE
  Wang *et al* ([@b27-etm-04-04-0762])             365    591       139        238    115    12     365    545    185    205    135    25     0.19   0.67   HWE
  Li *et al* ([@b28-etm-04-04-0762])               1023   1078      968        311    456    256    1052   1056   1048   257    542    253    1.54   0.21   HWE
  Liu *et al* ([@b29-etm-04-04-0762])              370    582       158        233    116    21     838    1334   342    528    278    32     0.38   0.54   HWE
  Lv *et al* ([@b30-etm-04-04-0762])               100    142       58         48     46     6      544    867    221    344    179    21     0.15   0.70   HWE
  Srivastava *et al* ([@b31-etm-04-04-0762])       228    363       93         147    69     12     230    328    132    122    84     24     2.66   0.10   HWE
  Chatterjee *et al* ([@b32-etm-04-04-0762])       445    455       435        102    251    92     1221   1255   1187   308    639    274    2.75   0.10   HWE
  Hart *et al* ([@b33-etm-04-04-0762])             436    460       412        125    210    101    433    421    445    106    209    118    0.50   0.48   HWE
  Kesarwani *et al* ([@b34-etm-04-04-0762])        170    244       96         86     72     12     198    301    95     109    83     6      4.42   0.04   Non-HWE
  Ma *et al* ([@b35-etm-04-04-0762])               218    343       93         128    87     3      285    398    172    138    122    25     0.07   0.79   HWE
  Theodoropoulos *et al* ([@b36-etm-04-04-0762])   402    407       397        103    201    98     480    494    466    120    254    106    1.68   0.19   HWE
  Umar *et al* ([@b37-etm-04-04-0762])             259    381       137        139    103    17     259    369    149    138    93     28     3.97   0.05   Non-HWE

CASP-8, caspase-8; HWE, Hardy-Weinberg equilibrium.

###### 

Meta-analysis of the association between the −652 6N ins\>del polymorphism in CASP-8 and cancer risk.

  Subgroup             Case no./N    Control no./N   OR (95% CI)         P-value   Effect model
  -------------------- ------------- --------------- ------------------- --------- --------------
  del allele           18220/46344   20678/51134     0.91 (0.84--0.98)   0.01      Random
    Caucasian          14597/30076   14943/30238     0.96 (0.93--1.00)   0.05      
    Asian              3188/15378    4548/18454      0.86 (0.75--1.00)   0.05      
    African            435/890       1187/2442       1.01 (0.87--1.18)   0.89      
  del allele carrier   14202/23172   16196/25567     0.87 (0.80--0.96)   0.005     Random
    Caucasian          10998/15038   11314/15119     0.89 (0.83--0.97)   0.005     
    Asian              2861/7689     3969/9227       0.86 (0.73--1.01)   0.06      
    African            343/445       913/1221        1.13 (0.88--1.47)   0.33      
  del/del              4018/23172    4482/25567      0.89 (0.79--1.01)   0.08      Random
    Caucasian          3599/15308    3629/15119      1.00 (0.95--1.05)   0.90      
    Asian              327/7689      579/9227        0.73 (0.53--1.01)   0.06      
    African            92/445        274/1221        0.90 (0.69--1.18)   0.44      
  ins/del              10184/23172   11741/25567     0.91 (0.85--0.98)   \<0.001   Random
    Caucasian          7399/125038   7685/15119      0.91 (0.84--0.98)   0.01      
    Asian              2534/7689     3390/9227       0.91 (0.80--1.03)   0.14      
    African            251/445       639/1221        1.18 (0.95--1.47)   0.14      

OR, odds ratio; 95% CI, 95% confidence interval.

###### 

Evaluation of publication bias by Egger's linear regression test.

  SNP                Coefficient   SE      t        P-value   95% CI
  ------------------ ------------- ------- -------- --------- -----------------
  del allele         −0.298        0.932   −0.320   0.753     (−2.265, 1.669)
  del carrier        0.375         0.834   0.450    0.658     (−1.384, 2.135)
  del/del genotype   −0.745        0.645   −1.160   0.264     (−2.105, 0.615)
  ins/del genotype   0.192         0.664   0.290    0.776     (−1.208, 1.592)

SE, standard error; 95% CI, 95% confidence interval.
